CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis

Soo, R. A.Cho, B. C.Kim, J-H.Ahn, M-J.Lee, K. H.Zimina, A.Orlov, S.2024-06-122024-06-1220230923-75341569-8041https://doi.org/10.1016/j.annonc.2023.09.2357https://hdl.handle.net/20.500.14551/25586Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- OCT 20-24, 2023 -- Barcelona, SPAIN[Abstract Not Available]en10.1016/j.annonc.2023.09.2357info:eu-repo/semantics/closedAccess[No Keywords]CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysisConference Object34N/AWOS:001087480202001